
News|Articles|November 17, 2026
Giredestrant Approval: What Nurses Need to Know and What Comes Next
Author(s)Alex Biese
Fact checked by: By ONN Staff
The evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.
Advertisement
Advertisement
The FDA approval of giredestrant (Wilserdly) plus everolimus (Afinitor) gives patients with ESR1-mutated, estrogen receptor (ER)–positive, HER2-negative advanced breast cancer an all-oral option after progression on endocrine-based therapy, and it places new testing, monitoring, and education responsibilities on oncology nurses, according to Erica L. Mayer, MD, MPH, principal investigator of the phase 3 evERA Breast Cancer trial.
Related to this article

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.

The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.

Modeling projects anthracycline recipients may lose a median 9.4 life-years to age acceleration, a finding with survivorship care implications.
Advertisement
Advertisement

